Home » Stocks » BeiGene

BeiGene Ltd. (BGNE)

Stock Price: $211.80 USD -3.58 (-1.66%)
Updated Aug 14, 2020 12:59 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 19.07B
Revenue (ttm) 224.73M
Net Income (ttm) -1.39B
Shares Out 90.02M
EPS (ttm) -20.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $211.80
Previous Close $215.38
Change ($) -3.58
Change (%) -1.66%
Day's Open 213.16
Day's Range 210.52 - 214.32
Day's Volume 41,518
52-Week Range 114.41 - 256.01

More Stats

Market Cap 19.07B
Enterprise Value 16.28B
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 90.02M
Float 44.66M
EPS (basic) -1.58
EPS (diluted) -20.22
FCF / Share -15.93
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.74M
Short Ratio 6.22
Short % of Float n/a
Beta 1.30
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 84.84
PB Ratio 7.87
Revenue 224.73M
Operating Income -1.43B
Net Income -1.39B
Free Cash Flow -1.24B
Net Cash 2.79B
Net Cash / Share 31.01
Gross Margin -253.78%
Operating Margin -637.63%
Profit Margin -620.50%
FCF Margin -550.69%
ROA -29.59%
ROE -67.89%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (19)

Buy 10
Overweight 5
Hold 4
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$237.70*
(12.23% upside)
Low
135
Current: $211.80
High
282
Target: 237.70
*Average 12-month price target from 18 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013
Revenue4281982381.078.8213.0411.15
Revenue Growth116.03%-16.85%22179.16%-87.86%-32.37%16.93%-
Gross Profit3571702331.078.8213.0411.15
Operating Income-960-706-98.46-117-56.75-15.76-5.57
Net Income-949-674-93.11-119-57.10-18.28-7.49
Shares Outstanding78172154340411199.8691.48
Earnings Per Share-1.22-0.93-0.17-0.30-0.52-0.18-0.08
Operating Cash Flow-750-54812.75-89.51-39.84-8.694.07
Capital Expenditures-89.61-70.28-58.73-23.50-5.31-0.65-0.25
Free Cash Flow-840-618-45.98-113-45.16-9.353.82
Cash & Equivalents9831,79683836810044.403.93
Total Debt27719816517.2820.7913.8427.36
Net Cash / Debt7061,59867335179.7030.56-23.44
Assets1,6122,2501,04640611753.6211.80
Liabilities63449636252.9142.4527.8548.76
Book Value9621,739670353-102-53.04-40.49
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name BeiGene Ltd.
Country China
Employees 4,200
CEO John V. Oyler

Stock Information

Ticker Symbol BGNE
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: BGNE
IPO Date February 3, 2016

Description

BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology cancer therapeutics in the People's Republic of China, the United States, and internationally. Its commercial products include BRUKINSA to treat R/R mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; KYPROLIS to treat multiple myeloma; BLINCYTO to treat acute lymphocytic leukemia; SYLVANT to treat idiopathic multicentric castleman disease; and QARZIBA to treat neuroblastoma. The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat various lymphomas; Tislelizumab, an anti-PD-1 antibody to treat various solid and hematological cancers; Pamiparib, an inhibitor of PARP1 and PARP2 to treat various solid tumors; Lifirafenib and BGB-3245 to treat various malignancies, such as melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumor. In addition, its clinical stage drug candidates include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; BGB-A1217, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; and BGB-A445, an OX40 agonist antibody to treat solid tumors. The company has collaborations with Celgene Corporation; Merck KGaA; Mirati Therapeutics, Inc.; BioAtla, LLC; Zymeworks, Inc.; Ambrx, Inc.; Atreca Inc.; IGM Biosciences, Inc.; and Hutchison China MediTech Limited. BeiGene, Ltd. was founded in 2010 and is based in Beijing, the People's Republic of China.